{"nctId":"NCT00661999","briefTitle":"Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer","startDateStruct":{"date":"2006-01"},"conditions":["Anemia","Leukemia","Lymphoma","Lymphoproliferative Disorder","Multiple Myeloma and Plasma Cell Neoplasm","Precancerous Condition","Unspecified Adult Solid Tumor, Protocol Specific"],"count":502,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Biological: darbepoetin alfa","Drug: sodium ferric gluconate complex in sucrose"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Biological: darbepoetin alfa","Dietary Supplement: ferrous sulfate"]},{"label":"Arm III","type":"EXPERIMENTAL","interventionNames":["Biological: darbepoetin alfa","Other: placebo"]}],"interventions":[{"name":"darbepoetin alfa","otherNames":[]},{"name":"ferrous sulfate","otherNames":[]},{"name":"sodium ferric gluconate complex in sucrose","otherNames":[]},{"name":"placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of a non-myeloid cancer (other than non-melanomatous skin cancer)\n* Receiving or scheduled to receive chemotherapy (biological agents, such as small molecules/tyrosine kinase inhibitors and antibody-based therapies, are allowed)\n* Has chemotherapy-related anemia (hemoglobin \\< 11 g/dL)\n\n  * No anemia known to be secondary to gastrointestinal bleeding or hemolysis\n  * No anemia known to be secondary to vitamin B12 or folic acid deficiency\n\n    \\+ Vitamin B12 and folic acid deficiency must be ruled out if the mean corpuscular volume (MCV) is \\> 100 fL\n  * No anemia secondary to chemotherapy-induced myelodysplastic syndromes\n* No primary hematologic disorder causing moderate to severe anemia (e.g., congenital dyserythropoietic anemia, homozygous hemoglobin S disease or compound heterozygous sickling states, or thalassemia major)\n\n  \\- Carriers for these disease states are eligible\n* No first-degree relative with primary hemochromatosis (unless the patient has undergone HFE genotyping and was found to have at least one wild-type allele, while the proband in the family demonstrated to have either the common C282Y or H63D mutation)\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Ferritin \\> 20 mcg/L (i.e., not obviously iron deficient)\n* ALT or AST \\< 5 times upper limit of normal\n* Alert, mentally competent, and able to sign informed consent\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for 3 months after completion of study treatment\n* Willing or able to be randomized and undergo study treatment\n* Willing or able to fill out quality-of-life forms\n* No uncontrolled hypertension (i.e., systolic blood pressure \\[BP\\] ≥ 180 mm Hg or diastolic BP ≥ 100 mm Hg)\n* No history of uncontrolled cardiac arrhythmias\n* No pulmonary embolism or deep venous thrombosis within the past year (unless the patient is on anticoagulation therapy and planning to continue it during study participation)\n* No known hypersensitivity to darbepoetin alfa, erythropoietin, mammalian cell-derived products, iron, or human albumin\n* No seizures within the past 3 months\n* No gastrointestinal conditions expected to cause significant impairment of oral iron, such as untreated celiac disease or amyloidosis involving the gut - Patients with celiac disease who are adhering to a gluten-free diet are eligible\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 3 months since prior darbepoetin alfa, epoetin alfa, or any investigational forms of erythropoietin (e.g., gene-activated erythropoietin or novel erythropoiesis-stimulating protein)\n* More than 1 year since prior peripheral blood stem cell or bone marrow transplantation\n* More than 2 weeks since prior red blood cell transfusions\n* More than 14 days since prior major surgery\n* No prior gastrectomy or resection of \\> 100 cm of small intestine\n* Not planning to undergo stem cell or bone marrow transplantation within the next 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hematopoietic Response Rate Defined as the Number of Participants Who Exhibit a Hematopoietic Response","description":"Hematopoietic response was defined as Hemoglobin (Hb) increment of 2.0 g/dL from baseline or achievement of Hb \\>= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"106","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"57","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Maintaining an Average Hemoglobin Level Within the National Comprehensive Cancer Network (NCCN) Range (11-13 g/dL) Through Week 16, Once Achieving a Hemoglobin of ≥ 11 g/dL","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Patients Receiving at Least One Red Blood Cell (RBC) Transfusions","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144","spread":null},{"groupId":"OG001","value":"142","spread":null},{"groupId":"OG002","value":"141","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Increment in Hemoglobin Level at Week 7","description":"Value at 7 weeks minus value at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.35"},{"groupId":"OG001","value":"1.1","spread":"1.37"},{"groupId":"OG002","value":"1.2","spread":"1.35"}]}]}]},{"type":"SECONDARY","title":"Mean Increment in Hemoglobin Level at Week 16","description":"Value at 16 weeks minus value at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"1.46"},{"groupId":"OG001","value":"2.0","spread":"1.61"},{"groupId":"OG002","value":"1.7","spread":"1.64"}]}]}]},{"type":"SECONDARY","title":"Time to Hematopoietic Response","description":"Hematopoietic response was defined as Hb increment of 2.0 g/dL from baseline or achievement of Hb \\>= 11 g/dL (whichever occurs first) in the absence of red blood cell transfusions during the preceding 28 days during the treatment period.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Red Blood Cell (RBC) Transfusions","description":null,"paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Overall Quality of Life (QOL) Score as Measured by the Linear Analogue Self Assessment (LASA)","description":"Overall QOL item score range: 0 (Worst) to 10 (Best), ordinal. Change: score at 16 weeks minus score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"2.18"},{"groupId":"OG001","value":"0.2","spread":"2.23"},{"groupId":"OG002","value":"0.5","spread":"2.28"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QOL) Score as Measured by Symptom Distress Scale (SDS) at End of Study","description":"SDS Scale range: 0 (Worst), 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.0","spread":"11.73"},{"groupId":"OG001","value":"3.5","spread":"11.54"},{"groupId":"OG002","value":"5.4","spread":"10.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QOL) Score as Measured by Brief Fatigue Inventory(BFI) Fatigue Now Scale at End of Study","description":"Fatigue Now Scale range: 0 (No Fatigue) to 10 (Worst), ordinal. Change: score at 16 weeks minus score at baseline.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"3.08"},{"groupId":"OG001","value":"-1.1","spread":"2.95"},{"groupId":"OG002","value":"-1.6","spread":"2.82"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quality of Life (QOL) Score as Measured by The Functional Assessment of Cancer Therapy-Anemia (FACT-An) at End of Study","description":"FACT-AN Scale range: 0 (Worst) to 100 (Best), ordinal. Change: score at 16 weeks minus score at baseline. A clinically significant result will be defined as a shift of 10 points on a 0-100 point transformed scale between the average QOL scores of the 3 variants of iron therapy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1","spread":"16.57"},{"groupId":"OG001","value":"8.9","spread":"18.97"},{"groupId":"OG002","value":"9.5","spread":"18.79"}]}]}]},{"type":"SECONDARY","title":"C-reactive Protein (CRP) Level at Week 1, Week 7 and Week 16","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":"38.12"},{"groupId":"OG001","value":"25.4","spread":"36.36"},{"groupId":"OG002","value":"31.6","spread":"58.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"51.09"},{"groupId":"OG001","value":"16.6","spread":"25.25"},{"groupId":"OG002","value":"27.0","spread":"49.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":"46.30"},{"groupId":"OG001","value":"16.7","spread":"36.98"},{"groupId":"OG002","value":"21.2","spread":"39.07"}]}]}]},{"type":"SECONDARY","title":"Soluble Transferrin Receptor (sTfR)Level at Week 1, Week 7 and Week 16","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"2.14"},{"groupId":"OG001","value":"4.0","spread":"1.99"},{"groupId":"OG002","value":"4.5","spread":"4.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"3.04"},{"groupId":"OG001","value":"6.2","spread":"2.4"},{"groupId":"OG002","value":"7.1","spread":"2.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"3.07"},{"groupId":"OG001","value":"5.2","spread":"2.19"},{"groupId":"OG002","value":"5.6","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Ferritin Level at Baseline, Week 7 and Week 16","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"460.5","spread":"526.99"},{"groupId":"OG001","value":"479.5","spread":"484.15"},{"groupId":"OG002","value":"456.0","spread":"479.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"699.1","spread":"645.31"},{"groupId":"OG001","value":"420.6","spread":"498.24"},{"groupId":"OG002","value":"478.4","spread":"607.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"726.0","spread":"1037.43"},{"groupId":"OG001","value":"425.9","spread":"717.43"},{"groupId":"OG002","value":"371.5","spread":"479.87"}]}]}]},{"type":"SECONDARY","title":"Mean Corpuscular Volume (MCV) Level at Baseline, Week 7 and Week 16","description":"MCV is a measure of the average red blood cell volume.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.0","spread":"5.92"},{"groupId":"OG001","value":"88.5","spread":"9.05"},{"groupId":"OG002","value":"90.1","spread":"8.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.0","spread":"9.21"},{"groupId":"OG001","value":"92.3","spread":"9.70"},{"groupId":"OG002","value":"92.8","spread":"8.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":"11.37"},{"groupId":"OG001","value":"94.4","spread":"7.55"},{"groupId":"OG002","value":"92.3","spread":"9.31"}]}]}]},{"type":"SECONDARY","title":"Transferrin Saturation at Baseline, Week 7 and Week 16","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":"12.81"},{"groupId":"OG001","value":"19.6","spread":"11.7"},{"groupId":"OG002","value":"22.2","spread":"13.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":"17.48"},{"groupId":"OG001","value":"26.4","spread":"23.56"},{"groupId":"OG002","value":"21.2","spread":"13.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":"14.16"},{"groupId":"OG001","value":"27.6","spread":"17.81"},{"groupId":"OG002","value":"23.9","spread":"15.54"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":164},"commonTop":["Nausea","Constipation","Diarrhea-No Colostom","Pruritus","Vomiting"]}}}